Placeholder Banner

BIO Comments to FDA on Rare Disease Endpoint Advancement Pilot Program Workshop: Novel Endpoints for Rare Disease Drug Development

July 20, 2023

BIO submitted comments on the recent Rare Disease Endpoint Advancement (RDEA) Pilot Program Workshop, held June 7-8, 2023 (Docket No. FDA-2022-N-2480)

Download Full Comments Below
BIO Comments to FDA on Rare Disease Endpoint Advancement Pilot Program Workshop: Novel Endpoints for Rare Disease Drug Development
Discover More
In response to the agency's request for information (Docket No. FDA-2023-N-0743-0002), BIO provides detailed comments.
BIO provides detailed comments in advance of the July 31, 2023 NIH Workshop, “Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.